Iron preparations

2024-2025

Growth in sales of drugs to eliminate iron deficiency in the body in Russia by 25% to ₽12,4 billion

Sales of iron products in the retail market of Russia increased by almost 25% in 2024 and reached ₽12,4 billion with the sale of almost 14 million packages of products for the treatment of iron deficiency conditions. In the first five months of 2025, Russians purchased over 6.2 million packages of iron preparations worth over ₽5,7 billion, which is 18.4% more than in the same period in 2024. This is evidenced by data from the analytical company RNC Pharma on July 16, 2025.

The largest manufacturers of iron products on the Russian market are:

• Servier with Sorbifer Durules - 27.0% of value sales;
• Sandoz with Ferrum Lek - 17.0%;
• Vifor Pharma with Ferinject - 10.8%;
• Italfarmaco with Ferlatum - 8.7%;
• Innotek Laboratory with Totema - 7.9%;
• Alzea with Ferretab - 7.6%;
• Vifor Pharma with Maltofer - 6.7%;
• Pierre Fabre with Tardiferon - 6.3%;
• Sotex with Liquferr 100 - 3.2%;
• Vifor Pharma with Venofer - 2.6%.

𝓲

Фото: Freepik

Sales of iron preparations have a pronounced seasonality, while the peaks in demand occur in the spring. In March-April 2025, more than 1.3 million packages were sold monthly, which is an absolute historical record, significantly ahead of even the highs of the spring excitement of 2022.

In this group, there is a wide price spread for the packaging of the product - from ₽100 to ₽10 thousand. Over the year, prices for these drugs increased by 14.4%, while in the analyzed period the average price for one package was ₽918.

According to the results of the first five months of 2025, there were more than 50 SKUs in the assortment of the retail segment of the iron drugs market, which is about 27 brands. The market is characterized by a high degree of concentration among leading manufacturers.^[1]

Notes